IL6 and COVID-19: The study revealed that both uncontrolled hypertension and long COVID resulted in elevated IL-6 and IL-17 concentrations, peaking in patients with both conditions and decreasing over time after infection, possibly reflecting Th17-related systemic inflammation during the acute phase of COVID-19.